NDAORALTABLET
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYLOREL (guanadrel sulfate) is an oral antiadrenergic agent approved in 1982 for hypertension management. It works by inhibiting norepinephrine release at peripheral adrenergic nerve terminals, reducing blood pressure through sympathetic nervous system suppression. The drug is a legacy therapeutic in a crowded antihypertensive market with modern alternatives.
LOE Approaching
With lifecycle status LOE-approaching and 30% competitive pressure, the brand team is likely in maintenance mode with minimal growth investment and reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYLOREL offers minimal career advancement opportunity given its LOE-approaching status and zero linked job openings. Roles are primarily transactional and maintenance-focused, with limited exposure to launch strategy, innovation, or international expansion.
Brand Manager (maintenance)Field Sales Representative
Worked on HYLOREL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.